Skip to main content

Advertisement

Table 2 List of all drug synergisms

From: Predicting and characterizing selective multiple drug treatments for metabolicdiseases and cancer

Drugs Side eff. Syn. ratio Class
Rosiglitazone (# 7) - Quinacrine (# 36) -Cerulenin (# 62) - Tyloxapol (# 85) 363.8 91 25.0% A
Rosiglitazone (# 7) - Quinacrine (# 36) - Orlistat(# 65) - Tyloxapol (# 85) 377.7 91 24.0% A
Rosiglitazone (# 7) - Indomethacin (# 22) - Cerulenin (# 62)- Tyloxapol (# 85) 390.6 91 23.2% A
Rosiglitazone (# 7) - Diclofenac (# 35) -Cerulenin (# 62) - Tyloxapol (# 85) 397.5 91 22.8% A
Rosiglitazone (# 7) - Indomethacin (# 22) - Orlistat(# 65) - Tyloxapol (# 85) 404.5 91 22.4% A
Rosiglitazone (# 7) - Diclofenac (# 35) - Orlistat(# 65) - Tyloxapol (# 85) 411.4 91 22.1% A
Rosiglitazone (# 7) - Cerulenin (# 62) 298.9 52 17.3% A
Rosiglitazone (# 7) - Orlistat (# 65) - 312.8 52 16.6% A
Indomethacin (# 22) - Fomepizole (# 75) 84.7 1 1.1% B
Naftifine (# 43) - Acetylsalicylic acid (# 55) 116.0 6 5.1% C
Acetylsalicylic acid (# 55) - Tioconazole (# 60) 116.0 6 5.1% C
Simvastatin/Pravastatin (# 4) - Acetylsalicylicacid (# 55) 123.9 6 4.8% C
Rosiglitazone (# 7) - Tioconazole (# 60) 280.9 6 2.1% C
Rosiglitazone (# 7) - Naftifine (# 43) 280.9 6 2.1% C
Simvastatin/Pravastatin (# 4) - Rosiglitazone(# 7) 288.8 6 2.0% C
Carbidopa (# 6) - Droxidopa (# 24) 93.1 1 1.0% D
Droxidopa (# 24) - Selegiline (# 45) 96.1 1 1.0% D
Droxidopa (# 24) - Minaprine (# 49) 152.4 1 0.6% D
Droxidopa (# 24) - Zonisamide (# 54) 289.7 1 0.3% D
Mycophenolic acid (# 42) - Mercaptopurine (# 58) 11.0 5 45.4% E
Ribavirin (# 51) - Mercaptopurine (# 58) 23.9 5 20.9% E
Udenafil (# 10) - Mycophenolic acid (# 42) -Mercaptopurine (# 58) - 18.0 7 38.8% E
Mycophenolic acid (# 42) - Dipyridamole (# 57) -Mercaptopurine (# 58) 22.0 7 31.8% E
Udenafil (# 10) - Ribavirin (# 51) - Mercaptopurine(# 58) 30.9 7 22.6% E
Ribavirin (# 51) - Dipyridamole (# 57) -Mercaptopurine (# 58) 34.9 7 20,0% E
Theophylline (# 18) - Mycophenolic acid (# 42) -Mercaptopurine (# 58) 41.7 7 16.7% E
Mycophenolic acid (# 42) - Pentoxifylline (# 50) -Mercaptopurine (# 58) 53.8 7 13.0% E
Theophylline (# 18) - Ribavirin (# 51) -Mercaptopurine (# 58) 54.6 6 10.9% E
Pentoxifylline (# 50) - Ribavirin (# 51) -Mercaptopurine (# 58) 66.7 6 8.9% E
Pentoxifylline (# 50) - Arsenic trioxide (# 72) 118.2 17 14.3% F
Cladribirne (# 16) - Pentoxifylline (# 50) 118.2 17 14.3% F
Gemcitabine (# 30) - Pentoxifylline (# 50) 157.8 15 9.5% F
  1. The table reports the multiple drug solutions in the human metabolicnetwork, the side effect σ(D), the synergism size(i.e. the number of stopped reactions which exceeds the linear superpositionof single drug effects), the ratio between these two quantities, and theirclassification (see Figure 2 and main text for theclustering analysis). Drug numbers refer to Additional file 1: Table S1. Bold font indicates that the solution (or part ofit) has an experimental validation.